Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity

References

• Ko Y H, Kim C W, Park C S, Jang H K, Lee S S, Kim S H, et al. REAL classification of malignant lymphomas in the Republic of Korea: Incidence of recently recognized entities and changes in clinicopathologic features. Cancer 1998; 83: 806–812
   PubMed Web of Science ®Google Scholar
• Proulx G M, Caudra-Garcia I, Ferry J, Harris N, Greco W R, Kaya U, et al. Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol 2003; 26: 6–11
   PubMed Web of Science ®Google Scholar
• Hirakawa S, Kuyama M, Takahashi S, Yamasaki O, Kanzaki H, Teshima T, et al. Nasal and nasal-type natural killer/T-cell lymphoma. J Am Acad Dermatol 1999; 40: 268–272
   PubMed Web of Science ®Google Scholar
• Liang R, Todd D, Chan T K, Chiu E, Lie A, Kwong Y L, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995; 13: 666–670
   PubMed Web of Science ®Google Scholar
• Au W Y, Ma S Y, Chim C S, Choy C, Loong F, Lie A K, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: A single center experience of 10 years. Ann Oncol 2005; 16: 206–214
   PubMed Web of Science ®Google Scholar
• Miller T P, Dahlberg S, Cassady J R, Adelstein D J, Spier C M, Grogan T M, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21–26
   PubMed Web of Science ®Google Scholar
• Li Y X, Yao B, Jin J, Wang W H, Liu Y P, Song Y W, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006; 24: 181–189
   PubMed Web of Science ®Google Scholar
• Lee J, Park Y H, Kim W S, Lee S S, Ryoo B Y, Yang S H, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005; 41: 1403–1408
   Web of Science ®Google Scholar
• Jaffe E S, Harris N L, Stein H, Vardiman J W. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. World Health Organization classification of tumors. IARC Press, LyonFrance 2001
   Google Scholar
• Chan J K, Ng C S, Lau W H, Lo S T. Most nasal/nasopharyngeal lymphomas are peripheral T-Cell neoplasms. Am J Surg Pathol 1987; 11: 418–429
   PubMed Web of Science ®Google Scholar
• Ng C S, Chan J K, Lo S T. Expression of natural killer cell markers in non-Hodgkin's lymphomas. Hum Pathol 1987; 18: 1257–1262
   PubMed Web of Science ®Google Scholar
• Chan J K, Tsang W Y, Pau M Y. Discordant CD3 expression in lymphomas as studied on frozen and paraffin sections. Hum Pathol 1995; 26: 1139–1143
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Cox D R. Regression models and life-tables. J Stat Soc 1982; 34: 187–220
   Google Scholar
• Cox J D, Stetz J, Pajak T F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341–1346
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. A revised European-American Classification of lymphoid neoplasm: a proposal from the International Lymphomas Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Kim W S, Song S Y, Ahn Y C, Ko Y H, Baek C H, Kim D Y, et al. CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma?. Ann Oncol 2001; 12: 349–352
   PubMed Web of Science ®Google Scholar
• Kim T M, Park Y H, Lee S Y, Kim J H, Kim D W, Im S A, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type. Blood 2005; 106: 3785–3790
   PubMed Web of Science ®Google Scholar
• Lee J, Sun C, Park Y H, Ko Y H, Bang S M, Lee J H, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612–618
   PubMed Web of Science ®Google Scholar
• Cheung M M, Chan J K, Lau W H, Ngan R K, Foo W W. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 182–190
   PubMed Web of Science ®Google Scholar
• Tham I W, Lee K M, Yap S P, Loong S L. Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy. Head and Neck 2005; 28: 126–134
   Web of Science ®Google Scholar
• Palmieri G, Lauria R, Caponigro F, Pagliarulo C, Montesarchio V, Nuzzo F, et al. Salvage chemotherapy for non Hodgkin's lymphoma of unfavorable histology with a combination of CCNU and vinblastine. Hematol Oncol 1990; 8: 179–183
   PubMed Web of Science ®Google Scholar
• Dorigo A, Mansberg R, Kwan Y L. Lomustine, etoposide, methotrexate and prednisone (LEMP) therapy for relapsed and refractory non-Hodgkin's lymphoma. Eur J Haematol 1993; 50: 37–40
   PubMed Web of Science ®Google Scholar
• Shamash J, Walewski J, Apostolidis J, Wilson A M, Foran J M, Gupta R K, et al. Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma. Ann Oncol 2000; 11: 857–860
   Google Scholar
• Musolino A, Perrone M A, Michiara M, Delnevo D, Franciosi V, Di Blasio B, et al. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma. Cancer 2005; 103: 2109–2117
   PubMed Web of Science ®Google Scholar
• Kim G E, Cho J H, Yang W I, Chung E J, Suh C O, Park K R, et al. Angiocentric lymphoma of the head and neck: Pattern of systemic failure after radiation treatment. J Clin Oncol 2000; 18: 54–63
   PubMed Web of Science ®Google Scholar
• Shikama N, Izuno I, Oguchi M, Gomi K, Sone S, Takei K, et al. Clinical stage IE primary lymphoma of the nasal cavity: Radiation therapy and chemotherapy. Radiology 1997; 204: 467–470
   PubMed Web of Science ®Google Scholar
• Li C C, Tien H F, Tang J L, Yao M, Chen Y C, Su I J, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004; 100: 366–375
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, et al. L-Asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Intl J Hematol 2003; 78: 163–167
   PubMed Web of Science ®Google Scholar
• Liang R, Chen F, Lee C K, Kwong Y L, Chim C S, Yau C C, et al. Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. Bone Marrow Transplant 1997; 19: 91–93
   PubMed Web of Science ®Google Scholar